Animal Tissues and Organs Transform into Biomaterials for Regenerative Medicine to Enter the World



ACRO Biomedical is a biotech company dedicated to the research and development of biomaterials for tissue engineering and regenerative medicine. With its unique "supercritical carbon dioxide (scCO2) decellularization platform technology", the cells, fat and non-collagenous proteins from animal tissues are removed, and the natural collagen scaffold is preserved as biomaterial for human tissue engineering and regenerative medicine. These biomaterials include class II and class III medical devices. ACRO Biomedical not only implements the concept of circular economy by whole pig application, but the medical devices it produces are also expected to become innovative materials that lead the regenerative medicine industry.

Dr. Dar-Jen Hsieh, CEO of ACRO Biomedical, emphasizes that this technology has solved the problem of the collagen medical industry for more than 60 years, "purification" no longer means "destroying the structure." Compared with the traditional decellularization processes which use strong acids and alkalis, surfactants, and organic solvents, ACRO Biomedical's technology is a minimal-manipulated process, there’s no chemical residues, hence high safety. The process retains the intact structure of collagen, and also has the advantages of high efficiency, and it can be applied to a variety of tissues or organs.

In addition, the collagen scaffold can be combined with stem cells and signaling factors corresponding to the tissue/organ even with the cells completely removed. These collagen scaffold biomaterials can be used in wound care, dentistry, orthopedics, ophthalmology, aesthetic medicine, cardiovascular specialties, urology, neurosurgery, and other professional fields.

This proprietary technology has obtained 55 patents including patents from China, the United States, Japan, South Korea, India, Taiwan, and the European Union. The medical device product derived from porcine skin and porcine bones have also obtained certificates from the United States, Taiwan, Singapore, the Philippines, and Vietnam.

Porcine skin-derived products comes in the form of wound matrix, barrier membrane, dermal particles, injectable matrix, and dermal patch can be used in burn wounds, surgical wounds, diabetic wounds, dentistry, otolaryngology, plastic surgery, anti-adhesive applications in neurosurgery and cardiac surgery, or soft tissue filling and hair regeneration for cosmetic purposes. Products derived from porcine bones include a variety of bone fillers used in orthopedics or dentistry.

In addition, ACRO has also developed the cornea product, which has a huge market demand for transplantation around the world. The clinical trials has been completed and the data has been submitted to the Ministry of Health and Welfare for review. It is anticipated that ACRO will obtain a class III medical device certificate by the end of the year. The collagen dermis particles product for medical aesthetics that promotes hair follicle regeneration are also under clinical trials.

It is worth noting that ACRO Biomedical is also simultaneously studying kidney reconstruction with Kaohsiung Medical University, heart reconstruction with the Tri-Service General Hospital, and liver reconstruction with National Taiwan University Hospital. It hopes to realize organ reconstruction in vivo through decellularized organ scaffolds. It is hoped that one day people will no longer have to wait in line for human donated organs for transplantation.